Award
National Institute of Allergy and Infectious Diseases 1R43AI188690-01A1
Development of well tolerated novel Inhibitors of drug resistant CMV
Recipient
MICROBIOTIX, INC
Award Amount
$298,582.00
Ceiling
$298,582.00
Awarded
August 07, 2025
Identifier
1R43AI188690-01A1
This award funds the development of novel inhibitors targeting drug-resistant cytomegalovirus (CMV) to reduce CMV-associated diseases in immunosuppressed patients. The project focuses on optimizing NAPA compounds to create effective and well-tolerated therapeutic candidates.
Description
Development of novel drugs against cytomegalovirus that will limit viral proliferation and significantly reduce cytomegalovirus-associated diseases in immunosuppressed patients. The project involves chemical optimization of NAPA compounds to generate 2-4 lead candidates for further testing. The research addresses significant public health needs related to CMV infections in immunocompromised patients.